Esperion Therapeutics ESPR Non-cash right of use asset
Non-cash right of use asset at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:NonCashRightOfUseAsset.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's non-cash right of use asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's non-cash right of use asset?
- Esperion Therapeutics (ESPR) reported non-cash right of use asset of $27K in Q1 2026.
- How has Esperion Therapeutics's non-cash right of use asset changed year-over-year?
- Esperion Therapeutics's non-cash right of use asset decreased by 10.0% year-over-year, from $30K to $27K.
- What is the long-term trend for Esperion Therapeutics's non-cash right of use asset?
- Over 2 years (2021 to 2024), Esperion Therapeutics's non-cash right of use asset has grown at a 281.7% compound annual growth rate (CAGR), from -$7K to $102K.
- What does non-cash right of use asset mean?
- This metric reflects the non-cash accounting adjustment associated with the recognition of right-of-use assets under lease accounting standards. It represents the value of the company's right to use an underlying asset for the lease term, which does not involve an immediate cash exchange. Analyzing this helps investors understand the company's long-term lease commitments and their impact on the balance sheet without distorting operating cash flow analysis.